Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Kyle B. Lupo, Sandro Matosevic
Cancers (2019) Vol. 11, Iss. 6, pp. 769-769
Open Access | Times Cited: 167

Showing 1-25 of 167 citing articles:

CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie, Han Dong, Yong Liang, et al.
EBioMedicine (2020) Vol. 59, pp. 102975-102975
Open Access | Times Cited: 603
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Tobias Bald, Matthew F. Krummel, Mark J. Smyth, et al.
Nature Immunology (2020) Vol. 21, Iss. 8, pp. 835-847
Open Access | Times Cited: 369
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
Annelisa M. Cornel, Iris Mimpen, Stefan Nierkens
Cancers (2020) Vol. 12, Iss. 7, pp. 1760-1760
Open Access | Times Cited: 323
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 277
Role of immune cells in the removal of deleterious senescent cells
Abhijit Kale, Amit Sharma, Alexandra Stolzing, et al.
Immunity & Ageing (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 258
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Gi‐Hoon Nam, Yoonjeong Choi, Gi Beom Kim, et al.
Advanced Materials (2020) Vol. 32, Iss. 51
Open Access | Times Cited: 226
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Hirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 217
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 125
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 114
Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions
Ashley Brauning, Michael Rae, Gina Zhu, et al.
Cells (2022) Vol. 11, Iss. 6, pp. 1017-1017
Open Access | Times Cited: 104
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
Roman M. Shapiro, Grace Birch, Guangan Hu, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 11
Open Access | Times Cited: 83
Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity
Benjamin Ruf, Tim F. Greten, Firouzeh Korangy
Nature reviews. Cancer (2023) Vol. 23, Iss. 6, pp. 351-371
Closed Access | Times Cited: 48
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Yaxian Kong, Jingyao Li, Xia Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 120
CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
Yu Yang Ng, Johan Chin-Kang Tay, Shu Wang
Molecular Therapy — Oncolytics (2019) Vol. 16, pp. 75-85
Open Access | Times Cited: 119
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 117
Blueprint for cancer research: Critical gaps and opportunities
Lynne W. Elmore, Susanna F. Greer, Elvan C. Daniels, et al.
CA A Cancer Journal for Clinicians (2020) Vol. 71, Iss. 2, pp. 107-139
Open Access | Times Cited: 87
Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy
Akram Al Abbar, Siew Ching Ngai, Nadine Nograles, et al.
BioResearch open access (2020) Vol. 9, Iss. 1, pp. 121-136
Open Access | Times Cited: 84
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
Kyle B. Lupo, Sandro Matosevic
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 83
Theranostic cells: emerging clinical applications of synthetic biology
Monica P. McNerney, Kailyn E. Doiron, Tai L. Ng, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 11, pp. 730-746
Open Access | Times Cited: 82
Adoptive Immunotherapy beyond CAR T-Cells
Aleksei Titov, Ekaterina Zmievskaya, Irina Ganeeva, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 743-743
Open Access | Times Cited: 78
Harnessing NK Cells for Cancer Treatment
Paola Minetto, Fabio Guolo, Silvia Pesce, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 77
Natural Killer Cells: Tumor Surveillance and Signaling
Lizeth G. Meza Guzman, Narelle Keating, Sandra E. Nicholson
Cancers (2020) Vol. 12, Iss. 4, pp. 952-952
Open Access | Times Cited: 77
Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
Rih‐Sheng Huang, Hsin-An Shih, Min‐Chi Lai, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 70
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Cristina Zalfa, Silke Paust
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top